| Year |
Citation |
Score |
| 2018 |
Dong F, Xu T, Wang X, Shen Y, Zhang X, Chen S, Zhong S, Zhang M, Ding Q. Lymph node dissection could bring survival benefits to patients diagnosed with clinically node-negative upper urinary tract urothelial cancer: a population-based, propensity score-matched study. International Journal of Clinical Oncology. PMID 30334174 DOI: 10.1007/s10147-018-1356-6 |
0.341 |
|
| 2018 |
Dong F, Xu L, Peng X, Xu T, Shen Y, Gao F, Wang X, Zhang X, Chen S, Zhang M, Zhong S, Ding Q. Pathologically examining a minimum of three lymph nodes could better determine node negativity in patients with non-metastatic chromophobe renal cell carcinoma. Japanese Journal of Clinical Oncology. PMID 30137442 DOI: 10.1093/jjco/hyy121 |
0.348 |
|
| 2018 |
Dong F, Fu H, Shi X, Shen Y, Xu T, Gao F, Wang X, Zhong S, Ding Q, Shen Z, Chen S. How do organ-specific metastases affect prognosis and surgical treatment for patients with metastatic upper tract urothelial carcinoma: first evidence from population based data. Clinical & Experimental Metastasis. PMID 29500709 DOI: 10.1007/s10585-018-9884-z |
0.353 |
|
| 2017 |
Xiong Z, Zang Y, Zhong S, Zou L, Wu Y, Liu S, Fang Z, Shen Z, Ding Q, Chen S. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent. Oncotarget. PMID 28404914 DOI: 10.18632/oncotarget.15620 |
0.325 |
|
| 2017 |
Dong F, Xu T, Shen Y, Zhong S, Chen S, Ding Q, Shen Z. Dysregulation of miRNAs in bladder cancer: altered expression with aberrant biogenesis procedure. Oncotarget. PMID 28187437 DOI: 10.18632/oncotarget.15173 |
0.301 |
|
| 2005 |
Zhong S, Abur A. Combined state estimation and measurement calibration Ieee Transactions On Power Systems. 20: 458-465. DOI: 10.1109/Tpwrs.2004.841237 |
0.467 |
|
| 2004 |
Zhong S, Abur A. Auto tuning of measurement weights in WLS state estimation Ieee Transactions On Power Systems. 19: 2006-2013. DOI: 10.1109/Tpwrs.2004.836182 |
0.466 |
|
| Show low-probability matches. |